Antipodes Partners’s Novanta NOVT Stock Holding History

Antipodes Partners’s Portfolio NOVT Stock Details NOVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-449	Closed	-$53.4K	–	147
2025 Q4	$53.4K	Buy	+449	New	+$51.1K	﹤0.01%	107

Other funds holding NOVT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Geneva Capital Management Milwaukee, Wisconsin $4.36B AUM 17.81% 1-Year Est. Return

Antipodes Partners's NOVT Position: Q1 2026 in Review

Antipodes Partners sold out of Novanta (NOVT) in Q1 2026, closing a stake of 449 shares — an estimated $53.4K sold.

Antipodes Partners first reported a position in NOVT in Q4 2025 and held it in 1 quarter. The position peaked at $53.4K in Q4 2025. 330 funds tracked by Wall St. Rank hold NOVT as of Q1 2026.

Antipodes Partners reported no remaining Novanta position as of Q1 2026 after selling out during the quarter.
Antipodes Partners sold 449 Novanta shares in Q1 2026, an estimated $53.4K.
Antipodes Partners first reported a position in Novanta in Q4 2025 and held it in 1 quarter.
Antipodes Partners's Novanta position peaked at $53.4K in Q4 2025.
330 funds tracked by Wall St. Rank held Novanta as of Q1 2026.

Based on Antipodes Partners's 13F filing for Q1 2026, filed 5 May 2026.